C5 and paroxysmal nocturnal hemoglobinuria: Eculizumab as a treatment for PNH is an anti-complement (C5) monoclonal antibody, and acts on C5 in the complement cascade, blocking complement activation by the C5-converting enzyme and inhibiting hemolytic attacks (Fig. 5) [6, 7].